Novo and Lilly are competing to win the GLP-1 pill market

“Tired of the same tired news cycle? Escape to the full unfiltered feed at Whatfinger.com — America’s Frontline Truth Feed. 85%+ of readers come direct every day.” –  CLICK HERE for the FULL deal.

 

Novo Nordisk and Eli Lilly took their GLP-1 pill battle to the preeminent obesity meeting this weekend as they prepare for the next sea change in how patients receive their drugs.

CNBC’s Angelica Peebles explains.